Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · November 27, 2024

Activity and Safety of Nintedanib in the Treatment of Patients With Lymphangioleiomyomatosis

The Lancet Respiratory Medicine

 

Additional Info

The Lancet Respiratory Medicine
Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
Lancet Respir Med 2024 Oct 25;[EPub Ahead of Print], S Harari, D Elia, A Caminati, J Geginat, F Luisi, G Pelosi, C Specchia, O Torre, R Trevisan, C Vasco, M Zompatori, R Cassandro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading